Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candesartan in chronic heart failure
NCT00843154Phase 3Terminated
- Sponsor
- Takeda
- Start
- Dec 2005
- Primary completion
- Jul 2008
- Modality
- Prodrugs/Conditional Activator Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of candesartan cilexetil in chronic heart failure (CHF) (2 arms), sponsored by Takeda. Primary endpoint: Brain Natriuretic Peptide at 12 weeks. Started Dec 2005; status: terminated.
02
Drugs
candesartan cilexetil
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NCT00843154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00843154.